Regulation (EU) 2017/745

Last updated

Regulation
European Union regulation
Flag of Europe.svg
TitleRegulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (Text with EEA relevance)
Made by Council
Made underTFEU/art 294 par 6
Journal reference L117, 5 May 2017 pp. 1–175
History
Date made5 April 2017
Entry into force25 May 2017
Implementation date(new date) 26 May 2021
Other legislation
ReplacesDirective 90/385/EEC, Directive 93/42/EEC
AmendsDirective 2001/83/EC, Regulation (EC) No 178/2002, and Regulation (EC) No 1223/2009
Current legislation

Regulation (EU) 2017/745 is a regulation of the European Union on the clinical investigation and placing on the market of medical devices for human use. It repealed Directive 93/42/EEC on Medical Devices (MDD) and Directive 90/385/EEC on active implantable medical devices (AIMDD).

Contents

The regulation was published on 5 April 2017 and came into force on 25 May 2017. [1] [2] [3]

Changes

Changes compared to the Medical Device Directive include changes in device classification and device scope, stricter oversight of manufacturers by notified bodies, introduction of the "Person Responsible for Regulatory Compliance" (PRRC) and of the economic operator concept, the requirement of Unique Device Identification marking for devices, EUDAMED registration (see below), UDI requirements, and increased postmarketing surveillance activities.

Scope and classification

Compared to the MDD, the scope of the MDR has been expanded to cover not only the active implantable medical devices previously covered by the Active Implantable Medical Device Directive 90/385/EWG (AIMDD) but also a range of products without an intended medical purpose. This category includes devices similar to medical devices, as listed in Annex XVI.

The classification rules of Annex VIII of the MDR have been expanded, compared to the MDD, to now 22 rules. Classification changes relate to software (rule 11), nanomaterials (rule 19), and substance-based medical devices (rule 21).

Reusable surgical instruments

Reusable surgical instruments are now included in their own category, often called "I R". As per § 120(3) of the regulation, aspects relating to their re-usability, are under the scope of Notified Body review starting 26 May 2024. This includes aspects relating to reprocessing and (re-)sterilization. This means that, with regard to Notified Body oversight, reusable surgical instruments are now treated similarly to sterile class I products and class I devices with a measuring function.

Products without an intended medical purpose

The scope of the MDR includes products without an intended medical purpose, that are similar in principle to medical devices but without a specific medical intended purpose. Annex XVI of the MDR lists the six categories of products that are covered by this scope. The groups includes devices such as cosmetic contact lenses, tattoo removal lasers, equipment for liposuction, and others. Instead of showing a clinical benefit, manufacturers of such products are required to demonstrate their performance and safety in the clinical evaluation.

Economic operator roles

The MDR in §2 (35) now defines several different roles for economic operators in relation to medical devices. The obligations of economic operators are detailed in the following sections:

Manufacturers, authorised representatives and importers have to register in the EUDAMED database to receive a Single Registration Number (SRN); only distributors of medical devices do not have to register.

Person responsible for regulatory compliance

The MDR in § 15 introduces the role of the "person responsible for regulatory compliance" (PRRC), that manufacturers and authorized representatives will have to have available within their organisation. The PRRC is assigned several duties and responsibilities, including making sure postmarketing surveillance obligations are fulfilled. Persons taking on the role and responsibilities of a PRRC have to meet certain qualitifcations with regard to education and experience. Further details on the PRRC are given in the EU guidance MDCG 2019–7.

General safety and performance requirements

The "General Safety and Performance Requirements" (GSPR) of the MDR replace the "Essential Requirements" (ER) of the MDD. Annex I of the MDR lists 23 requirements, divided in three chapters:

Compared to the MDD ER, the MDR GSPR have been expanded, e.g. with regards to devices for lay use, IT security, and devices without a medical purpose. Manufacturers are expected to utilize harmonized standards and common requirements to demonstrate conformance to the GSPR.

European database on medical devices

The EUropean DAtabase on MEdical Devices (EUDAMED) is a database to collect and publish information on medical devices and in-vitro-diagnostica.

EUDAMED has six modules:

Data on economic operators, devices registration and certificates are available to the public. The database will allow to link manufacturer's certification and Single Registration Number (SRN) as well as the Basic UDI. The so-called "Summary of Safety and Clinical Performance" (SSCP), required for some high-risk medical devices, will also be accessible to the public through the database. More details on the operation of EUDAMED are given in Commission Implementing Regulation (EU) 2021/2078. A similar database is the Global Unique Device Identification Database (GUDID) of the FDA.

As a key to EUDAMED, the MDR introduces the Basic UDI-DI as unique device identifier. A medical device (including system- and procedure packs and IVD) needs to have an assigned Basic UDI-DI and needs to be registered in the UDI/Device part of EUDAMED. Devices with their own UDI-DI from the same manufacturer with same intended purpose, risk class and essential design and manufacturing characteristics can be grouped under one Basic UDI. [4] Legacy devices that do not have a previously assigned Basic UDI-DI, they are assigned an EUDAMED-DI for the purpose of registration in EUDAMED. [5] Instead of the UDI-DI, an EUDAMED ID can be assigned for registration. [6]

Medical Device Coordination Group

In accordance with §103 of the MDR, the Medical Device Coordination Group (MDCG) has been established. The MDCG and its sub-groups publish guidances that provide clarification and support to national competent authorities, notified bodies and economic operators on the details of the implementation of the MDR and IVDR. The members of the MDCG are experts appointed by the EU member states. [7]

History

Origins and background

The previous legal framework included the 'New Approach' directive on medical devices (MDD) that had become an accepted industry standard and been updated by Directive 2007/47/EC. In 2010, the French authorities recalled breast implants manufactured by the french company Poly Implant Prothèse in what became known as the PIP scandal. The company had received a CE certificate by Notified Body TÜV Rheinland but used un-certified silicone for the products. This incident created significant public concern over the adequacy of the regulatory framework in ensuring medical device safety. This led to the development of an action plan (the so-called PIP Joint Action Plan) in 2012 by the European Union to strengthen market surveillance and develop new regulations for medical devices. [8] [9] The revision of European medical device regulations through by the repeal of the MDD and introduction of the MDR aimed to address existing gaps, improve Notified Body oversight, market surveillance, and enhance patient safety.

Implementation date

The regulation was adopted, and came into force, in 2017. The date by which the Regulation was to be fully implemented by replacing the previous directives was originally defined as 26 May 2020. Following the international health emergency COVID-19, the European Commission and the European Parliament decided in April 2020 to postpone the deadline by one year to 26 May 2021. [10]

Additional provisions for the transition from MDD to MDR are found in Article 120 of the regulation. Due to certain issues, some additional transition timelines were implemented in 2023, amending Article 120 and allowing for some delays in re-certification up until 2028 for class III and IIB implantable devices, and for 2027 for some others, under certain circumstances; the "sell-off" provision of MDD-licensed devices, previously May 2025, was also removed. [11]

Other changes and amendments

A requirement for manufacturers on notifying authorities digitally about (potential) medical device supply chain disruptions was added to the regulation in 2024 (§10a). [12] [13]

In October 2024, the European Parliament has adopted a resolution to update the Medical Devices and In Vitro Diagnostics Regulations to prevent potential product shortages, and proposing a timeline of Q1 2025 for the EU Commission to present delegated and implementing acts and proposed changes to the regulations. This decision responds to manufacturers' concerns about meeting transition deadlines. [14] [15]

See also

Related Research Articles

<span class="mw-page-title-main">Biomedical engineering</span> Application of engineering principles and design concepts to medicine and biology

Biomedical engineering (BME) or medical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare applications. BME is also traditionally logical sciences to advance health care treatment, including diagnosis, monitoring, and therapy. Also included under the scope of a biomedical engineer is the management of current medical equipment in hospitals while adhering to relevant industry standards. This involves procurement, routine testing, preventive maintenance, and making equipment recommendations, a role also known as a Biomedical Equipment Technician (BMET) or as a clinical engineer.

<span class="mw-page-title-main">Restriction of Hazardous Substances Directive</span> European Union directive restricting ten hazardous materials

The Restriction of Hazardous Substances Directive 2002/95/EC, short for Directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment, was adopted in February 2003 by the European Union.

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">CE marking</span> European Declaration of conformity mark

The presence of the logo on commercial products indicates that the manufacturer or importer affirms the goods' conformity with European health, safety, and environmental protection standards. It is not a quality indicator or a certification mark. The CE marking is required for goods sold in the European Economic Area (EEA); goods sold elsewhere may also carry the mark.

<span class="mw-page-title-main">Medical device</span> Device to be used for medical purposes

A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country. As a general rule, as the associated risk of the device increases the amount of testing required to establish safety and efficacy also increases. Further, as associated risk increases the potential benefit to the patient must also increase.

Regulatory affairs (RA), is a profession that deals with an organization’s adherence to regulatory compliance.

Type approval or certificate of conformity is granted to a product that meets a minimum set of regulatory, technical and safety requirements. Generally, type approval is required before a product is allowed to be sold in a particular country, so the requirements for a given product will vary around the world. Processes and certifications known as type approval in English are often called homologation, or some cognate expression, in other European languages.

ISO 13485Medical devices -- Quality management systems -- Requirements for regulatory purposes is a voluntary standard, published by International Organization for Standardization (ISO) for the first time in 1996, and contains a comprehensive quality management system for the design and manufacture of medical devices. The latest version of this standard supersedes earlier documents such as EN 46001 and EN 46002 (1996), the previously published ISO 13485, and ISO 13488.

Postmarketing surveillance (PMS), also known as post market surveillance, is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance. Since drugs and medical devices are approved on the basis of clinical trials, which involve relatively small numbers of people who have been selected for this purpose – meaning that they normally do not have other medical conditions which may exist in the general population – postmarketing surveillance can further refine, or confirm or deny, the safety of a drug or device after it is used in the general population by large numbers of people who have a wide variety of medical conditions.

<span class="mw-page-title-main">Medical Devices Directive</span>

The Medical Device DirectiveCouncil Directive 93/42/EEC of 14 June 1993 concerning medical devices—is intended to harmonise the laws relating to medical devices within the European Union. The MD Directive is a 'New Approach' Directive and consequently in order for a manufacturer to legally place a medical device on the European market the requirements of the MD Directive have to be met. Manufacturers' products meeting 'harmonised standards' have a presumption of conformity to the Directive. Products conforming with the MD Directive must have a CE mark applied. The Directive was most recently reviewed and amended by the 2007/47/EC and a number of changes were made. Compliance with the revised directive became mandatory on 21 March 2010.

A European Authorised Representative (E.A.R.) serves as a legal entity designated by non European Union (EU) manufacturers, to represent them in the EU and ensure their compliance with the European Directives. The CE certificate and declaration of conformity can only be issued by a company located in the European Union.

The Italian Ministry of Health (MOH) has implemented mandatory procedures for the Italian registration of medical devices as of 1 May 2007.

Design controls designates the application of a formal methodology to the conduct of product development activities. It is often mandatory to implement such practice when designing and developing products within regulated industries.

<span class="mw-page-title-main">Notified body</span>

A notified body, in the European Union, is an organisation that has been designated by a member state to assess the conformity of certain products, before being placed on the EU market, with the applicable essential technical requirements. These essential requirements are publicised in European directives or regulations.

The Unique Device Identification (UDI) System is intended to assign a unique identifier to medical devices within the United States, Europe, China, South Korea, Saudi Arabia and Taiwan. It was signed into law in the US on September 27, 2007, as part of the Food and Drug Administration Amendments Act of 2007.

ISO 14971Medical devices — Application of risk management to medical devices is a voluntary consensus standard, published by International Organization for Standardization (ISO) for the first time in 1998, and specifies terminology, principles, and a process for risk management of medical devices.

The Machinery Directive, Directive 2006/42/EC of the European Parliament and of the Council of 17 May 2006 is a European Union directive concerning machinery and certain parts of machinery. Its main intent is to ensure a common safety level in machinery placed on the market or put in service in all member states and to ensure freedom of movement within the European Union by stating that "member states shall not prohibit, restrict or impede the placing on the market and/or putting into service in their territory of machinery which complies with [the] Directive".

<span class="mw-page-title-main">Regulation (EU) 2017/746</span>

Regulation (EU) 2017/746 (IVDR) is a regulation of the European Union on the placing on the market and putting into service of in vitro diagnostic medical devices (IVD), repealing Directive 98/79/EC (IVDD), which also concerned IVD. The regulation was published in April 2017 and is closely aligned to the EU regulation on medical devices. Changes compared to the IVDD include changes in device classification, stricter oversight of manufacturers by Notified Bodies, introduction of the "Person Responsible for Regulatory Compliance" (PRRC), the requirement of UDI marking for devices, common specifications, Eudamed registration, and increased post-market surveillance activities.

A custom-made medical device, commonly referred to as a custom-made device (CMD) or a custom device, is a medical device designed and manufactured for the sole use of a particular patient. Examples of custom-made medical devices include auricular splints, dentures, orthodontic appliances, orthotics and prostheses.

References

  1. "Regulatory framework – Growth – European Commission". Growth. 12 May 2020. Archived from the original on 3 May 2018. Retrieved 12 April 2018.
  2. Duhs, Gustaf (27 March 2018). "A new landscape for medical devices". pharmatimes.com. Archived from the original on 12 July 2024. Retrieved 12 April 2018.
  3. "Regulatory Affairs Professionals Society | RAPS". Archived from the original on 24 May 2018. Retrieved 12 April 2018.
  4. "EUDAMED" (PDF). Archived (PDF) from the original on 12 July 2024. Retrieved 12 July 2024.
  5. "What about Legacy devices?". EU UDI Helpdesk. Archived from the original on 3 August 2021.
  6. "EUDAMED" (PDF). Archived (PDF) from the original on 31 March 2023. Retrieved 12 July 2024.
  7. https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en
  8. https://ec.europa.eu/commission/presscorner/detail/en/ip_14_699
  9. https://ec.europa.eu/commission/presscorner/api/files/document/print/en/ip_14_699/IP_14_699_EN.pdf
  10. "Texts adopted - Medical devices ***I - Friday, 17 April 2020". Archived from the original on 21 April 2020. Retrieved 21 April 2020.
  11. Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices
  12. Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain in vitro diagnostic medical devices (OJ L, 2024/1860, 9.7.2024, ELI: http://data.europa.eu/eli/reg/2024/1860/oj).
  13. https://alvamed.com/newsletter/eu-publishes-regulation-eu-2024-1860-amid-device-supply-chain-concerns/
  14. https://www.raps.org/news-and-articles/news-articles/2024/10/eu-parliament-passes-resolution-citing-%E2%80%98urgent-nee?utm_campaign=regulatory-focus&utm_source=linkedin&utm_medium=social
  15. https://www.europarl.europa.eu/doceo/document/TA-10-2024-0028_EN.html